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Background: Canine lymphoma represents the most frequent haematopoietic cancer and it shares some
similarities with human non-Hodgkin lymphoma. Matrix metalloproteinases (MMPs) and vascular endothelial growth
factor (VEGF) play a coordinated role during invasion and proliferation of malignant cells; however, little is known
about their role in canine haematologic malignancies. The aim of this study was to investigate the mRNA and
protein expression of VEGF and the most relevant MMPs in canine lymphoma. Lymph node aspirates from 26 B-cell
and 21 T-cell lymphomas were collected. The protein expression levels of MMP-9, MMP-2 and VEGF-A were
evaluated by immunocytochemistry, and the mRNA levels of MMP-2, MMP-9, MT1-MMP, TIMP-1, TIMP-2, RECK,
VEGF-A and VEGF-164 were measured using quantitative RT-PCR.
Results: MT1-MMP, TIMP-1 and RECK mRNA levels were significantly higher in T-cell lymphomas than in B-cell
lymphomas. Higher mRNA and protein levels of MMP-9 and VEGF-A were observed in T-cell lymphomas than in
B-cell lymphomas and healthy control lymph nodes. A positive correlation was found between MMP-9 and VEGF-A
in T-cell lymphomas. Moreover, MMP-9, MT1-MMP, TIMP-1 and VEGF-A were expressed at the highest levels in high-grade
T-cell lymphomas.
Conclusions: This study provides new information on the expression of different MMPs and VEGF in canine lymphoma,
suggesting a possible correlation between different MMPs and VEGF, immunophenotype and prognosis.
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Canine lymphoma is a heterogeneous group of neoplastic
disorders and different subtypes are characterized by dif-
ferent morphology, pathophysiology and clinical behav-
iour [1,2]. Different reports in human medicine have
shown that lymphoproliferative tumours are able to pro-
duce extra cellular matrix (ECM)-degrading enzymes with
proteolytic activity. In this context, matrix metallopro-
teinases (MMPs) have been demonstrated to have a role
in the pathogenesis of lymphoma and be of prognostic sig-
nificance [3,4]. MMPs are zinc-dependent enzymes re-
sponsible for the degradation of the ECM components,* Correspondence: luca.aresu@unipd.it
1Department of Comparative Biomedicine and Food Science, University of
Padova, Viale dell'Università 16, 35020, Agripolis Legnaro, PD, Italy
Full list of author information is available at the end of the article
© 2013 Aricò et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orincluding the basement membrane, a natural barrier with
a key role in preventing invasion and migration of tumour
cells [5]. Tumour cells can self-produce and secrete
MMPs to promote invasion and increase their metastatic
potential [6]. Once MMPs are released, their proteolytic
activity is controlled by the activation of latent proen-
zymes and by the inhibition of activated proteinases.
These processes are controlled by tissue inhibitor meta-
lloproteinases (TIMPs) that are co-secreted by MMP-
producing cells [5]. Among MMPs, MMP-2 and MMP-9
play a critical role in the modification of ECM and tumour
invasion. Activation of MMP-2 occurs at the cell surface
and is mediated by membrane type-1 MMP (MT1-MMP)
[7]. A new MMP inhibitor, reversion-inducing cysteine-
rich-protein with Kazal motifs (RECK), was reported to
down-regulate different MMPs in dogs [8]. MMP-9 is atd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cinogenesis, increasing the availability of vascular endo-
thelial growth factor (VEGF) in a sort of vicious circle [9].
Recently, VEGF has received considerable attention in ca-
nine solid neoplasia [10,11]. We applied the concept of
tumour microenvironment to canine leukaemia and de-
monstrated that VEGF could stimulate new blood vessels
growth and increase endothelium permeability for sys-
temic dissemination of leukaemic cells [12]. In human
lymphoma, VEGF has two potential roles: increase of
angiogenesis and proliferation and/or survival of lympho-
ma cell induced by autocrine vascular endothelial growth
factor receptor-mediated signalling [9].
In a previous work in dogs, we demonstrated that
plasma levels of MMP-9 and VEGF are higher in B-cell
and T-cell lymphomas with respect to healthy dogs and
that their levels significantly decreased in B-cell lymph-
omas during chemotherapy [13]. The role of these pro-
teins in canine lymphoma is still unclear and only scarce
data are available in veterinary medicine [13-16]. The
aim of the present study was to assess the gene expres-
sion profiles of MMP-2, MMP-9, MT1-MMP, TIMP-1,
TIMP-2, RECK, VEGF-A and VEGF-164 and the protein
levels of MMP-2, MMP-9 and VEGF-A in canine B and
T-cell lymphomas.Methods
Chemicals
The chemicals, reagents and kits used in this study
were obtained from the following companies: foetal
bovine serum, sodium azide, ammonium chloride, po-
tassium bicarbonate, ethylenediaminetetraacetic acid,
methanol and acetone were obtained from Sigma
Aldrich (Munich, Germany); RPMI 1640 medium was
obtained from Sigma Aldrich (Munich, Germany) or
PAA, (Pasching, Austria), fetal calf serum (FCS),
penicillin, streptomycin were obtained from PAA,
(Pasching, Austria); May–Grunwald–Giemsa was
obtained from Merck KGaA (Frankfurt, Germany);
L-glutamine was obtained from Mediatech Inc. (Herndon,
VA, USA); RNAlater® solution and High Capacity cDNA
Reverse Transcription Kit were obtained from Applied
Biosystems (Foster City, CA, USA); the RNeasy Mini
Kit, RNase-Free DNase set and the QuantiTect Reverse
Transcription Kit were obtained from Qiagen (Milan,
Italy); the LightCycler 480® Probe Master and the
human Universal Probe Library (UPL) probe were
obtained from Roche Diagnostics (Basel, Switzerland);
primer pairs were obtained from Eurofins MWG Operon
(Ebersberg, Germany); and biotinylated anti-mouse sec-
ondary antibody, diaminobenzidine substrate, and haema-
toxylin were obtained from Ventana Medical Systems
(Tucson, AZ, USA).Caseload, cell lines and classification
Fine-needle aspirates (FNAs) of enlarged lymph nodes
obtained from dogs with lymphoma were collected. Sam-
ples were sent by the referring veterinarians to the Depart-
ment of Veterinary Pathology, Hygiene and Health at the
University of Milan, and to the Department of Animal
Pathology at the University of Turin for diagnostic pur-
poses. The study was approved and granted by MIUR
PRIN 2008, protocol 20085MSFH2.
The different subtypes were described according to the
updated Kiel classification [17] by considering pleomorph-
ism; cell size; nuclear shape; chromatin density; mitotic
index; the number, size and distribution of nucleoli; and
the extension and basophilia of the cytoplasm. The
immunophenotype was determined by means of flow cy-
tometry with the use of the following monoclonal anti-
bodies: CD45-PEb (clone YKIX716.13, Serotec, Oxford,
UK, leukocytes), CD3-FITC (clone CA17.2A12, Serotec, T
cells), CD4-FITC (clone YKIX302.9, Serotec, T-helper cells
and neutrophils), CD8-PE (clone YCATE55.9, Serotec,
T-cytotoxic/suppressors), CD5 (clone YKIX322.3, T-cells),
CD21-PE (clone CA21D6 Serotec, mature B cells), CD34-
PE (clone 1H6, Pharmingen, Becton Dickinson, San Jose,
CA, precursor cells), and CD79a (clone HM57, Dako,
Atlanta, GA, all stages of B-cells). Data acquisition was
performed by using a FACSCalibur (Becton Dickinson),
and the analysis was conducted with a commercially avai-
lable software (Cell Quest, Becton Dickinson). The expres-
sion of specific lineage markers defined the lineages of
lymphoma: CD3, CD5, CD4, and/or CD8 for T-cell
lymphomas, and CD21 and CD79a for B-cell lymphomas.
A positive staining referred to the antigen expression in at
least 20% of the gated cells. Samples being characterized
by an ambiguous diagnosis, low cellularity or viability
were excluded from the present study. Five healthy dogs
with no relevant peripheral lymph node alterations served
as controls. Informed consent was obtained from all
owners according to the regulations of each institutional
animal care committee.
Two canine lymphoma cell lines (CLBL-1, B-cell lymph-
oma [18], and OSW, T-cell lymphoma [19]) were used for
the study [18,19]. The cell lines were maintained in RPMI
1640 cell culture medium supplemented with 10% heat
inactivated FCS, penicillin 100 U/ml/streptomycin 0.1
mg/ml at 37°C in a humidified atmosphere of 5% CO2.
Sampling procedure
Two samples were obtained from each lymph node FNA
for routine cytological assessment and flow cytometry,
and for immunocytochemical analysis and total RNA
extraction. For flow cytometry, cells were suspended in
0.5 mL of RPMI 1640 medium containing 5% foetal bo-
vine serum and 0.2% sodium azide at room temperature.
The remaining material was washed twice in the same
Table 1 qRT-PCR assay parameters: primer concentration,







TMBIM4 F600/R300 90.2 0.00291 23.90 – 32.39
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at −20°C for total RNA isolation.
Total RNA extraction, at least 0.5 mL, of each cell sus-
pension containing 2 × 106 cell/mL of good viability was
used for lymphoma cell lines.MMP-2 F600/R600 100.2 0.03450 25.57 – 32.68
MMP-9 F300/R300 99.8 0.05740 30.50 – 36.28
MT1-MMP F600/R600 100.1 0.02890 24.64 – 31.68
TIMP-1 F600/R300 100.0 0.03110 25.24 – 31.25
TIMP-2 F300/R300 103.4 0.02890 24.50 – 31.38
RECK F600/R300 101.0 0.06310 27.05 – 33.78
VEGF-A F300/R300 102.8 0.01020 26.56 – 32.49
VEGF-164 F300/R300 99.8 0.02690 28.54 – 35.19
F, forward primer; R, reverse primer.Quantitative real-time RT-PCR (qRT-PCR)
The total RNA was isolated from both cell pellets and
RNAlater® suspensions, as recommended by Dunmire et al.
[20], using the RNeasy Mini Kit according to the manufac-
turer’s instructions. To avoid genomic DNA contami-
nation, on-column DNase digestion with the RNase-Free
DNase set was performed. The total RNA concentration
and quality were measured using a Nanodrop ND-1000
spectrophotometer (Nanodrop Technologies, Wilmington,
DE) and by denaturing gel electrophoresis. First-strand
cDNA was synthesised from 200 ng of total RNA using
the High Capacity cDNA Reverse Transcription Kit and
the QuantiTect Reverse Transcription Kit for FNAs and
lymphoma cell lines, respectively, according to the manu-
facturer’s protocol. The generated cDNA was then used as
the template for qRT-PCR in a LightCycler 480 Instru-
ment (Roche Diagnostics) using standard PCR conditions.
The qRT-PCR reactions consisted of 1× LightCycler 480®
Probe Master, 300 or 600 nM forward and reverse primers
(the primer combination and final concentrations were
optimised during the assay setup), 100 nM human UPL
probe and 2.5 μL of 25-fold-diluted cDNA. Primer pairs
and human UPL probes for MMP-2, MMP-9, MT1-MMP,
TIMP-1, TIMP-2, RECK and VEGF-A amplification were
described previously [6,10]. In the present study, VEGF-
164, the VEGF-A splice variant markedly expressed in
dogs and highly conserved among species [21] was also
considered. Canine VEGF-164 was amplified using the pri-
mer pair 5′-CGT GCC CAC TGA GGA GTT-3′ (for-
ward) and 5′-AAG GCC CAC AGG GAT TTT CT-3′
(reverse) and human UPL probe #9. The concentration of
each set of primers was optimised to efficiently amplify its
target. Agarose gel electrophoresis confirmed the ampli-
fication of a single amplicon of the expected size. Calibra-
tion curves using a 4-fold serial dilution of a cDNA pool
revealed PCR efficiencies comprised in the range of ac-
ceptance (90-110%) and error values < 0.2 (see Table 1).
The canine transmembrane BAX inhibitor motif con-
taining 4 (TMBIM4 or CGI-119) [22] was chosen as refe-
rence gene for the absence of statistically significant
differences in its expression profile between the healthy
and pathologic samples. Moreover its amplification effi-
ciency was approximately equal to those of the target
genes. The relative quantification of messenger RNA was
performed using the ΔΔCt method [23]. The relative
quantification values were ultimately expressed as arbi-
trary units.Immunocytochemical analysis
The protein expression levels of MMP-2, MMP-9 and
VEGF-A of the lymphoma samples and the cell lines were
evaluated by immunocytochemistry. The cellular suspen-
sion designated for immunocytochemical analysis was pre-
pared by cytospin and fixed with acetone and methanol.
Sections of five normal lymph nodes were used for immu-
nohistochemical analysis. The primary antibody incubation
step was performed by an automated system for all anti-
bodies (Ventana Medical Systems). The antibodies used in
this study were the following: anti-human MMP-9, Clone
C-TERM (1:200; Millipore S.p.A, Milan, Italy); anti-human
MMP-2, Clone Ab-7 (1:100; Thermo Fisher Scientific Inc.,
Kalamazoo, Michigan, USA); and anti-human VEGF-A,
Clone A-20 – sc:152 (1:200; Santa Cruz Biotechnology,
Inc., Santa Cruz, California, USA). The Ventana ES au-
tomated immunohistochemistry system was used for the
remainder of the staining procedure, including the incuba-
tion with a biotinylated anti-mouse secondary antibody,
the diaminobenzidine substrate and a haematoxylin coun-
terstain. Positive controls for MMP-2 and MMP-9 con-
sisted of fibroblasts and granulocytes in sections of canine
mammary tumours [6]. The endothelial cells in normal
skin were used as positive control for VEGF-A [11]. Nega-
tive control slides were incubated with isotype-matched
immunoglobulin in parallel with each staining batch to
confirm the specificity of the antibodies. Immunoreactivity
for MMP-2, MMP-9 and VEGF-A was scored in the fol-
lowing manner: 0: <10% positive cells, 1: 10–24% positive
cells; 2: 25–49% positive cells; 3: >50% positive cells. The
image analysis system included an Olympus BX51 micro-
scope and a software analysis (analySIS, Soft imaging sys-
tem, Münster, Germany).
Gelatin zymography
MMP-2 and MMP-9 activity of the lymphoma samples
was studied by zymography. Briefly, the cells were lysate
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concentration of the supernatant was measured. The
sample protein concentration was adjusted to 1 mg/ml,
and 5 μl was diluted 1:1 in sample buffer; the final 10 μl
sample was subjected to electrophoresis on an 8% SDS-
PAGE gel copolymerized with 0.1% gelatin. Following
electrophoresis, the gel was incubated for 1 h at room
temperature in a 2.5% Triton X-100 solution and then
at 37°C for 16 h in 0.5 M Tris–HCl buffer, pH 7.4, with
10 mM CaCl2. The gels were stained with 0.1%
Coomassie Brilliant Blue R-250 and de-stained with 30%
methanol and 10% acetic acid. Gelatinolytic activities
were detected as unstained bands against the back-
ground of Coomassie-stained gelatin. Culture medium
conditioned by A2058 melanoma cells was used as a
control to identify the pro-MMP-9 gelatinolytic band,
whereas conditioned media from HT1080 fibrosarcoma
cells was used for the active forms of MMP-2 and
MMP-9 and small amounts of the pro-MMP-2 [24].Statistical analysis
The statistical analysis of the gene expression results was
performed using Mann–Whitney test and Kruskal-Wallis
test followed by Dunn’s post-test. A non-parametric
Spearman correlation analysis was used to determine the
potential relationship between target genes and between
gene expression levels and percentage of neoplastic cells
in B and T-cell lymphomas. GraphPad Prism 5 software
(San Diego, California, USA) was used for all statistical
evaluations. Statistical significance was set at p<0.05.
Finally, Grubbs’ test was used to identify potential outliers.Results
Clinical results
Forty-seven dogs with multicentric lymphoma were en-
rolled. Based on cytological and flow cytometric evalu-
ation, there were 26 B-cell lymphomas (22 high-grade, HG,Table 2 MMP-9, MMP-2, MT1-MMP, TIMP-1, TIMP-2, VEGF-A, V
nodes, B-cell and T-cell lymphomas, CLBL-1 and OSW lympho
Genes Control lymph nodes B-cell lymphoma
MMP-2 0.96 ± 0.23a,b 0.24 ± 0.28
TIMP-2 0.85 ± 0.34a,b 0.15 ± 0.20
MT1-MMP 0.61 ± 0.17a 0.11 ± 0.11c
MMP-9 0.13 ± 0.11b 0.12 ± 0.04 c
TIMP-1 0.15 ± 0.09b 0.16 ± 0.22 c
RECK 0.29 ± 0.12b 0.06 ± 0.12c
VEGF-A 0.37 ± 0.19b 0.71 ± 0.98
VEGF-164 0.57 ± 0.23 0.63 ± 0.92
Data are expressed as relative quantification values (arbitrary units, mean ± SD).
a, b, c Significant differences between control lymph nodes and B-cell lymphoma, co
lymphoma, respectively (Kruskal-Wallis test followed by Dunn’s post test; p < 0.05).and 4 low-grade, LG), and 21 T-cell lymphomas (13 HG
and 8 LG).
qRT-PCR
The gene expression results for healthy control lymph
nodes, B-cell and T-cell lymphomas, and cells lines are
summarised in Table 2. MMP-2 and TIMP-2 mRNA
levels in the healthy control lymph nodes were signifi-
cantly higher than in lymphomas (p<0.05). Significantly
higher MMP-9 and TIMP-1 mRNA expression levels
were observed in T-cell lymphomas compared to B-cell
lymphomas and healthy controls (p<0.05). Furthermore,
a statistically significant higher MT1-MMP mRNA amount
was observed in T-cell lymphomas compared to B-cell
lymphomas (p<0.05). MT1-MMP mRNA levels were
also significantly higher in control lymph nodes than in
B-cell lymphomas (p<0.05). When considering the tis-
sue inhibitor RECK, statistically significant differences
were observed between B-cell and T-cell lymphomas,
and between T-cell lymphomas and healthy controls
(p<0.05).
B-cell and T-cell lymphomas had similar VEGF-A and
VEGF-164 expression profiles, moreover T-cell lympho-
mas showed significantly higher expression of VEGF-A
with respect to controls (p<0.05).
Interestingly, higher MMP-9, MT1-MMP, VEGF-A,
VEGF-164 and TIMP-1 mRNA expressions were ob-
served in HG T-cell lymphomas compared to LG T-cell
lymphomas, although the differences were not statisti-
cally significant (Table 3). The same analysis was not
performed in B-cell lymphomas because of the low num-
ber of LG cases included in the study.
The expressions of MMP-9, MT1-MMP, TIMP-1 and
RECK were significantly higher in HG T-cell lymphomas
compared to HG B-cell lymphomas (p<0.05) (Table 3).
Although not statistically significant, VEGF-A and VEGF-
164 mRNA expressions showed the same trend. Signifi-
cant correlations between MMP-2 and TIMP-2 (p<0.001;EGF-164 and RECK mRNA expression in control lymph
ma cell lines
T-cell lymphoma CLBL-1 OSW
0.16 ± 0.29 0.00 0.00
0.16 ± 0.29 0.00 0.82
0.94 ± 0.99 0.04 4.11
0.69 ± 0.11 0.76 1128.35
0.66 ± 0.75 0.72 2.38
0.87 ± 1.12 4.32 19.56
0.89 ± 1.37 4.87 1.42
0.90 ± 1.38 7.99 3.18
ntrol lymph nodes and T-cell lymphoma, B-cell lymphoma and T-cell
Table 3 MMP-9, MMP-2, MT1-MMP, TIMP-1, TIMP-2,
VEGF-A, VEGF-164 and RECK mRNA expression in high
grade and low grade T-cell lymphomas and HG B-cell
lymphomas
Genes T-cell lymphoma B-cell lymphoma
tt High grade Low grade High grade
MMP-2 0.18 ± 0.22 0.17 ± 0.20 0.26 ± 0.29
MMP-9 0.82 ± 0.15 a 0.12 ± 0.28 0.01 ± 0.03
MT1-MMP 1.01 ± 1.08 a 0.81 ± 0.86 0.10 ± 0.11
TIMP-1 1.07 ± 1.98 a 0.63 ± 0.92 0.13 ± 0.21
TIMP-2 0.15 ± 0.28 0.16 ± 0.32 0.14 ± 0.19
RECK 0.93 ± 1.26 a 1.67 ± 2.76 0.06 ± 0.12
VEGF-A 1.21 ± 1.65 0.35 ± 0.43 0.67 ± 0.99
VEGF-164 1.11 ± 0.92 0.39 ± 0.88 0.49 ± 0.65
Data are expressed as relative quantification values (arbitrary units, mean ± SD)
aSignificant difference between high grade T-cell and B-cell lymphomas
(Mann–Whitney test; p < 0.05).
Figure 1 B-cell lymphoma FNAs. (a) low number of positive
immunoassayed lymphoid tumour cells for MMP-2 antibody (arrow);
(b) numerous positive immunoassayed lymphoid tumour cells for
MMP-9 antibody (arrow); (c) plasma cells and low percentage of
immunoassayed lymphoid tumour cells for VEGF-A antibody
(arrows). Immunocytochemistry, 400×.
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(p<0.01; Spearman r=0.67) were found in T-cell lympho-
mas. No statistically significant correlations were found
between gene expression and the percentage of neoplastic
cells in B-cell and T-cell lymphomas.
The gene expression results for cell lines are summa-
rised in Table 2. A higher MMP-9 mRNA expression was
observed in OSW compared to CLBL-1; whereas MMP-2
mRNA was undetectable in both cell lines. MT1-MMP
and TIMP-1 mRNAs were detected in OSW, but no re-
sults were obtained for CLBL-1. VEGF-A and VEGF-164
transcripts were detected in both cell lines. In CLBL-1 and
OSW, TIMP-2 and TIMP-1 mRNA expressions were
close to 0, whereas RECK was detected.
Immunocytochemical analysis
The immunocytochemical expression of MMP-9 was
grade 3 in 16 T-cell lymphomas (13 HG and 3 LG) and
grade 2 in the remaining T-cell lymphomas (5 LG),
whereas in 21 B-cell lymphomas the expression was
grade 1 (18 HG and 3 LG) and grade 2 in the remaining
cases (4 HG and 1 LG). MMP-2 expression was grade 2
in all T-cell lymphomas; grade 1 in 19 HG B-cell lymph-
omas and grade 0 in the remaining 7 B-cell lymphomas
(3 HG and 4 LG). VEGF-A labelling was scored grade 2
in 19 T-cell lymphomas (13 HG and 6 LG), grade 1 in 2
LG T-cell lymphomas and all the B-cell lymphomas.
Representative images of MMP-9, MMP-2 and VEGF-A
immunolabelling in lymphomas are shown in Figures 1
and 2. The expression of MMP-2, MMP-9 and VEGF-A
was grade 0 in the 5 control lymph nodes (Figure 3a, 3b
and 3c). MMP-9 was highly expressed in OSW (92%)
whereas expression was weaker in CLBL-1 (19%)
(Figure 4a and 4b). No MMP-2 expression was found inboth cell lines. CLBL-1 and OSW showed VEGF-A posi-
tive immunolabelling (22%) (Figure 4c and 4d). The
mean immunocytochemical scores are shown for B-cell
lymphomas, T-cell lymphomas and control lymph nodes
in Table 4.
Figure 2 T-cell lymphoma FNAs. Intense and widespread
positive immunoassayed lymphoid tumour cells for (a) MMP-2
antibody, (b) MMP-9 antibody and (c) VEGF-A antibody.
Immunocytochemistry, 400×.
Figure 3 Control lymph nodes. Scattered positive immunoassayed
lymphocytes for MMP-2 (a), MMP-9 (b) and VEGF-A
(c). Immunohistochemistry, 200×.
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Both latent and active forms of MMP-2 and MMP-9 were
undetectable at gelatine zymography in lymphoma samples.
Discussion
In human haematologic malignancies, VEGF and dif-
ferent enzymes involved in ECM remodelling, includingMMPs, are considered molecules for early diagnosis and
prognostic assessment [25-27]. Recently, we suggested a
potential role of MMP-9, MT1-MMP, TIMP-1, TIMP-2
and VEGF in the pathogenesis of canine leukaemia [12].
In this study we investigated the role of different MMPs,
their regulators and VEGF in canine lymphoma by asse-
ssing mRNA and protein expression profiles.
Figure 4 Cell lines. a) low number of positive immunoassayed cells in CLBL-1 for MMP-9 antibody b) intense and widespread positive
immunoassayed cells in OSW for MMP-9 antibody, c) low number of positive immunoassayed cells in CLBL-1 for VEGF-A antibody, d) low number
of positive immunoassayed cells in OSW for VEGF-A antibody. Immunocytochemistry, 400×.
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were observed in T-cell lymphomas compared to B-cell
lymphomas and healthy control lymph nodes, indicating
that MMP-9 may be associated with tumour phenotype.
In human non-Hodgkin lymphoma a trend toward an
unfavourable prognosis and MMP-9 expression has been
demonstrated [28]. When we compared HG and LG
lymphomas, MMP-9 overexpression was found in HG
T-cell lymphomas respect with LG T-cell lymphomas.
HG T-cell lymphomas are characterized by organ inva-
sion and bone marrow infiltration, and are considered
highly aggressive [2]. Biologically, T-cells are able to mi-
grate across ECM barriers during the inflammatory
process towards target tissues and the activation of
MMP-9 causes alteration of adjacent connective tissues
and degradation of collagen type IV [29]. The immuno-
histochemical results in normal lymph nodes sections
identified a low number of MMP-9 positive cells in area
compatible with germinal centres and paracortex,Table 4 Immunocytochemical scores for MMP-9, MMP-2
and VEGF-A in B-cell lymphomas, T-cell lymphomas and
control lymph nodes expressed as mean (min-max)
MMP-9 MMP-2 VEGF-A
HG B-cell lymphomas 22.1% (13–35) 16.9% (3–22) 17.3% (11–23)
LG B-cell lymphomas 15.7% (11–27) 4.2% (2–7) 13.8% (12–17)
HG T-cell lymphomas 79.8% (56–89) 38.4% (29–45) 44.7% (38–48)
LG T-cell lymphomas 41.3% (25–63) 30.2 (26–33) 30.2% (18–37)
Control lymph nodes 4.2% (1–7) 0.8% (0–2) 0.8% (0–2)indicating that normal B-cells are also able to express a
minimum amount of MMP-9. However, T-cells might be
able to increase MMP-9 production during the neoplas-
tic transformation more than B-cells. MMP-9 results in
CLBL-1 and OSW cells additionally confirmed the dif-
ferent MMP-9 expression both at the mRNA and pro-
tein level in B- and T-cell lymphomas. The equivalent
expression value of the T-cell lymphoma samples and
the CLBL-1 cell line could be due to a difference in pri-
mary material and a cell line. Nevertheless, the very high
expression in the OSW cells strongly supports the hy-
pothesis for T-cell expression. This data also seems to
exclude a possible interference of the microenvironment
in MMP-9 regulation.
Significantly higher levels of TIMP-1 mRNA were ob-
served in T-cell lymphomas compared to B-cell lymph-
omas and controls. This same result was obtained also
in vitro, as the T-cell lymphoma cell line (OSW) showed
about 3-fold TIMP-1 mRNA higher amount than B-cell
lymphoma cell line (CLBL-1). Overall, this experimental
evidence supports the hypothesis that MMP-9 and TIMP-
1 may act in concert in canine T-cell lymphoma. MMP-9
is frequently expressed and secreted with TIMP-1 by ca-
nine neoplastic cells [6,12]. These molecules are associ-
ated with a more aggressive clinical behaviour in human
lymphoma, and they appear to exert their influence
through two different mechanisms: MMP-9 causes ECM
degradation, whereas TIMP-1 shows an anti-apoptotic
action [30,31]. The same may hold true in dog where HG
T-cell lymphomas showed a higher TIMP-1 mRNA ex-
pression than LG.
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of control lymph nodes, whereas B-cell and T-cell lymph-
omas exhibited minimal to moderate amount of MMP-2.
Interestingly, mRNA expression was significantly higher
in control dogs with respect to dogs with lymphoma. The
mRNA expression in control lymph nodes may be altered
by the presence of a variable number of cells that are nor-
mally found within the node and in the perinodal tissue,
such as fibroblasts and plasmacells, constitutively express-
ing MMP-2 [6]. Furthermore, in different solid tumours,
variable MMP-2 protein amounts with insignificant ex-
pression of MMP-2 mRNA have been shown and corre-
lated to feedback mechanisms, being able to shut off
messenger expression after the secretion and/or binding
of the protein [32]. A different post-transcriptional regula-
tion of MMP-2 or indirect mechanisms of activation may
be hypothesised in lymphomas. Hypoxia, macrophages,
granulocytes and endothelial cells are known to activate
MMP-2 in tumour invasion and angiogenesis but the spe-
cific mechanism of MMP-2 activation in vivo is yet not
fully understood. Activation of proMMP-2 and concomi-
tant induction of MT1-MMP mRNA expression has been
found in human fibroblasts, endothelial cells, and breast
carcinoma cells [33]. In T-cell lymphomas MT1-MMP
mRNA levels were higher compared to B-cell lymphomas
and in HG T-cell lymphomas with respect to LG lymph-
omas. This phenomenon was also seen in the two cell
lines. This result identifies a different biological behaviour
for this transcript based on the phenotype and morpho-
logical features. Besides MT1-MMP, other auxiliary com-
ponents such as TIMP-2 and integrins are required for
activation of pro-MMP-2. It has been shown that TIMP-2
plays a critical role in MMP-2 activation on the cell sur-
face by binding to MT1-MMP [5]. Interestingly, in T-cell
lymphomas MMP-2 qRT-PCR analysis revealed a signifi-
cant positive correlation with TIMP-2. Unfortunately we
were not able to perform immunohistochemistry for
MT1-MMP and TIMP-2 in the present work.
We also performed gelatine zymography in T-cell and
B-cell lymphomas to investigate the activity of MMP-2
and MMP-9, but no catalytic activity was detected.
While it is relatively easy to detect MMPs in media
obtained from cell culture, the extraction and analysis of
MMPs and TIMPs from cells are much more difficult
and the number of cells might influence detection [34].
A possible limit in the study is the lack of lymphoma tis-
sue; so far, further experiments should be directed to
identify the catalytic activity of MMP-9 and MMP-2 in
B-cell and T-cell lymphomas.
In both T- and B-cell lymphomas, we observed VEGF-A
expression at the mRNA and protein level. HG T-cell
lymphomas showed higher VEGF-A mRNA expression
compared with LG T-cell lymphomas and moreover the
mRNA VEGF-A results were correlated with MMP-9results in T-cell lymphomas. These data appear to be in
accordance with our previous work, in which we reported
a close relationship between MMP-9 and VEGF plasmatic
levels in canine lymphomas [13]. We also observed the
same results in canine mast cell tumours, in which the re-
lease of VEGF by mast cells is correlated with higher
MMP-9 production [10]. Indeed, the feedback activation
between MMP-9 and VEGF is implicated in the angio-
genic switch. In fact VEGF-A is known to be the most im-
portant mediator of angiogenesis. In the present study we
could not associate VEGF-A protein and gene expression
results to an increased microvessel density but this was
demonstrated to be not significant in a precedent work
[35]. Interestingly, cell lines showed a similar result for
VEGF-A and VEGF-164 which was fairly high in both cell
lines compared to the primary material. Furthermore, the
different results for gene expression and protein data in
normal lymph nodes may confirm an overexpression of
VEGF-A in canine lymphoma.
Conclusion
In conclusion, our data provide new information on the
expression of different MMPs and VEGF in canine
lymphoma. Further efforts should be directed towards
clarifying the detailed molecular mechanisms of MMPs,
such as signal transduction and proteolytic activity. In
human non-Hodgkin lymphoma, functional VEGF poly-
morphisms, which have an effect on the regulation of
gene expression, contribute to the differences between
individuals. Future investigations will be directed in this
direction in canine lymphoma. The results from this
study also indicate that differences between lymphoma
subtypes must be taken into account in the selection of
the most suitable canine patients for trials with anti-
angiogenic agents and MMPs inhibitors.
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